LBRX
LB Pharmaceuticals Inc Common Stock- Healthcare
- Biotechnology
- $1.28B market cap
Forecast run · Sep 15, 2026Upside rank 918 of 3,136
Model Signal
ForecastQ Daily Probabilities
46.1%
32.9%
26.6%
Analyst Consensus
Recommendation2.00/5 Buy
Last price$44.63
Price target$51.86
Implied move+16.2%
Analysts3
ForecastQ Portfolios
LBRX is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.
Company Profile
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.